PhereSys Therapeutics Expands Senior Management Team to Initiate Therapeutic Apheresis Operations Throughout the Midwest.

EL DORADO HILLS, Calif. -- - PhereSys Therapeutics Corporation announced today the establishment of its Midwest Regional therapeutic apheresis (TA) operations based in Chicago and Minneapolis. Patricia Golden, BSN, RN and Christine Fernandez, BSN, RN have been appointed Vice Presidents and Co-Regional Directors and bring over 40 years of combined experience in therapeutic apheresis ('TA") to the Company. The opening of the Midwest region is a part of the Company's strategic plan to build the nation's most comprehensive, contract mobile TA network.

Ms. Golden was responsible for the development of the therapeutic apheresis program at Kidney Disease and Critical Care Associates serving the Minneapolis and St. Paul areas, which grew to more than 1,500 procedures per year. After Fresenius Medical Care of North America (FMC-NA) assumed control of the program, she advanced to the position of Corporate Director of Therapeutic Apheresis. Currently, Ms. Golden is the President of the American Society of Apheresis (ASFA), an organization specializing in the training and education of apheresis practitioners. Ms. Golden has conducted numerous educational programs on therapeutic apheresis and has authored and co-authored a number of journal articles. She is active in several professional societies, and has committee appointments to the American Society for Clinical Pathology (ASCP) Globalization Task Force, ASFA Public Affairs Committee, ASFA Allied Health Committee, and the American Society for Hematology, Committee on Practice. Ms. Golden has been Chair of the ASFA/ASCP Hemapheresis Practitioner Certification Examination Committee for three years. She is also the ASFA liaison to the ASCP Board of Registry, Board of Governors.

Ms. Fernandez was involved in the development of the Hematopoetic Cell Transplant and Therapeutic Apheresis Programs at Riley Hospital for Children at Indiana University Medical Center and has implemented and monitored several apheresis and hematopoetic transplant programs in the Chicago area. From 2002 until recently, Ms. Fernandez was the National Director of Operations for Therapeutic Apheresis with Fresenius Medical Care Extracorporeal Alliance, which performs over 4,500 procedures annually. Currently, Ms. Fernandez sits on the board of directors of ASFA. She has made numerous educational presentations both nationally and internationally on apheresis and has authored and co-authored a number of journal articles in the field of apheresis and hematopoetic transplantation. She is currently working on a project to facilitate apheresis education and certification in Mexico. Ms. Fernandez is active in several professional societies and has committee appointments to ASFA's Allied Health, International Affairs and the Annual Meeting Planning committees.

"We are extremely pleased that Pat and Christine have decided to join our senior management team and manage our Midwest operations." said Richard Davis, MD, Chairman and Chief Executive Officer of PhereSys Therapeutics. "Both Pat and Christine have demonstrated life-long commitments to the field of apheresis and bring tremendous expertise to our growing company. Their practical experiences fit perfectly with our goal of delivering the highest quality, most innovative therapeutic services to hospitals and physicians offices on a national level."

About PhereSys Therapeutics Corporation

PhereSys Therapeutics is a privately held company founded to establish the premier contract mobile therapeutic apheresis services network in the United States. The Company currently provides its services to hospitals and physicians' offices in California and New York. PhereSys is scaling up an aggressive nationwide expansion of its business model with new initiatives now underway in Minnesota, Illinois, Michigan, Wisconsin and Texas. At least 10 other states are scheduled for operations in the coming year. In addition to being the preferred mobile provider of the RHEO(R) system, once approved by the FDA, PhereSys' strategy involves establishing strategic relationships with TA providers, blood banks, and TA technology companies, as well as assisting pharmaceutical and biotech companies seeking to develop and commercialize stem cell and other advanced cellular therapies.

Forward Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may vary. We do not undertake to update any forward-looking statements.